Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
HEPHAISTOS-Pharma logo — Developing the weapons that we need to defeat cancer.

HEPHAISTOS-Pharma

Developing the weapons that we need to defeat cancer.

Founded 2018 France France 15 employees Seed Total: $7.07M Biotechnology

General Information

Company Name HEPHAISTOS-Pharma
Founded Year 2018
Location France France
Employees 15
Industries Biotechnology
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with HEPHAISTOS-Pharma. To contact HEPHAISTOS-Pharma, visit hephaistos-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does HEPHAISTOS-Pharma compare?

A PDF of HEPHAISTOS-Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting HEPHAISTOS-Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About HEPHAISTOS-Pharma

HEPHAISTOS-Pharma is a biotechnology startup that aims to revolutionize cancer treatment through the development of anti-tumoral immunotherapies. Founded in 2018 and headquartered in France, the company has a clear mission encapsulated in its slogan, "Developing the weapons that we need to defeat cancer." Their innovative approach focuses on enhancing the efficacy of monoclonal antibodies and enabling the treatment of previously untreatable tumors. In their latest funding round in 23 January 2024, HEPHAISTOS-Pharma secured a significant investment of €4.50M from a diverse group of investors including Angels Santé, Elaia, Noshaq, xista science ventures, Fournier-Majoie, and Femmes Business Angels. This backing not only reflects confidence in the company's potential but also provides the necessary resources for further research and development. With a strong focus on disrupting the biotechnology industry and addressing a critical need in cancer treatment, HEPHAISTOS-Pharma's progress in enhancing immunotherapies is poised to make a notable impact. As the company continues to advance, the support from a diverse group of investors not only validates their approach but also positions them for broader recognition and potential future success.

Business keywords: immunotherapy, oncology, cancer treatment, monoclonal antibodies, tumor therapy, biopharmaceuticals, bio-innovation, drug development, therapeutic innovation

Services & Products

Design and development of sole-in-class innate immune sensor modulators for cancer treatment

Target Customers

Patients with immune-resistant cold tumors clinicians oncologists pharmaceutical companies research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Hephaistos €4.50M 6
Angels Santé Elaia Noshaq
Angels Santé, Elaia +4
23 Jan 2024
Grant Hephaistos €2.50M 1
EIC Accelerator
31 Oct 2023
Grant Hephaistos Undisclosed 2
Bpifrance
Bpifrance, France 2030
01 Feb 2023
Grant Hephaistos €71.43K 1
EASME - EU Executive Agency for SMEs
01 Jan 2019

Latest News

View All
French biotech HEPHAISTOS-Pharma gets €4.5 million to develop next-gen of immunostimulants against c... — Eu-startups
French biotech HEPHAISTOS-Pharma gets €4.5 million to develop next-gen of immunostimulants against cancer
Eu-startups May 16, 2024

HEPHAISTOS-Pharma Alternatives & Competitors

View All Alternatives
HEPHAISTOS-Pharma vs
ADC Biotechnology
ADC Biotechnology

Accelerating solutions for developers to overcome conjugation challenges, making new ADC-based anti-...

Venture round
Biopharma, Biotechnology
HEPHAISTOS-Pharma vs
Oncofactor Corporation
Oncofactor Corporation

A Seattle-based innovator in cancer treatments, disrupting tumor-immune system signaling pathways.

Venture round
1 employees
Biotechnology, Health Care
HEPHAISTOS-Pharma vs
GLIKNIK INC.
GLIKNIK INC.

Harnessing innovation to empower immune responses and combat cancer with advanced peptide, immunoglo...

Series C
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About HEPHAISTOS-Pharma

Developing the weapons that we need to defeat cancer.
HEPHAISTOS-Pharma was founded in 2018.
HEPHAISTOS-Pharma is headquartered in France.
HEPHAISTOS-Pharma operates in Biotechnology. Its work centres on immunotherapy, oncology, cancer treatment and monoclonal antibodies. Its customers include Patients with immune-resistant cold tumors, clinicians and oncologists.
HEPHAISTOS-Pharma has approximately 15 employees.
HEPHAISTOS-Pharma has completed 4 funding rounds, raising a total of $7.07M. The latest funding stage is Seed.
HEPHAISTOS-Pharma offers: Design and development of sole-in-class innate immune sensor modulators for cancer treatment.
Top alternatives and competitors to HEPHAISTOS-Pharma include ADC Biotechnology, Oncofactor Corporation, GLIKNIK INC., Agensys, Alderaan Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HEPHAISTOS-Pharma and ADC Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for HEPHAISTOS-Pharma, https://bouncewatch.com/company/hephaistos-pharma, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes